Stifel analyst Annabel Samimy reiterated a Buy rating and $60.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst comments "While ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Cowen Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS), 'We Remain Optimistic For Pegcetacoplan Approval'August 9, 2022 4:01 AM Roth Capital Reiterates Sell Rating on Apellis Pharmaceuticals (APLS), Street Low $40 PTAugust 9, 2022 3:58 AM UPDATE: Apellis Pharmaceuticals (APLS) PT Raised to Street High $113 at Raymond JamesAugust 9, 2022 3:57 AM UPDATE: Apellis Pharmaceuticals (APLS) PT Raised to $52 at Credit SuisseAugust 9, 2022 3:34 AM UPDATE: Apellis Pharmaceuticals (APLS) PT Raised to $102 at Goldman SachsAugust 9, 2022 3:21 AM Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5cAugust 8, 2022 4:18 PM Apellis Pharmaceuticals Reports Second Quarter 2022 Financial ResultsAugust 8, 2022 4:06 PM Apellis Pharmaceuticals Reports Second Quarter 2022 Financial ResultsAugust 8, 2022 4:05 PM Form 4 Apellis Pharmaceuticals, For: Aug 04 Filed by: DeLong Mark JeffreyAugust 8, 2022 4:03 PM Form 10-Q Apellis Pharmaceuticals, For: Jun 30August 8, 2022 4:03 PM